医学
曲妥珠单抗
帕妥珠单抗
内科学
多西紫杉醇
肿瘤科
乳腺癌
炎症性乳腺癌
化疗
癌症
作者
Özlem Özdemir,Baha Zengel,Yaşar Yıldız,Başak Oyan Uluç,Devrim Çabuk,Ercan Özden,Derya Kıvrak Salim,Semra Paydaş,Atakan Demir,Ömer Diker,Kezban Nur Pilancı,Özlem Sönmez,Sezai Vatansever,İzzet Doğan,Ahmet Gülmez,Burcu Çakar,Pınar Gürsoy,Mahmut Emre Yıldırım,Murat Ayhan,Nuri Karadurmuş
出处
期刊:Anti-Cancer Drugs
[Lippincott Williams & Wilkins]
日期:2022-06-15
卷期号:33 (7): 663-670
被引量:4
标识
DOI:10.1097/cad.0000000000001310
摘要
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
科研通智能强力驱动
Strongly Powered by AbleSci AI